Mereo BioPharma Group plc(MREO)

$0.27—

Chart

Mereo BioPharma Group plc(MREO)

NASDAQ

$0.27—

Chart Studio

MREO(MREO)

MREO

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.01

Nov 9, 2026 · Reports before open

Revenue Estimate

$863,830

Analyst Sentiment

Wall St. Consensus

Buy

8 analysts·Limited coverage

Score

5 Buy (63%)2 Hold (25%)1 Sell (12%)

Rating Breakdown

Strong Buy

00%

Buy

563%

Hold

225%

Sell

113%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$0.50

+87.4%

Consensus

$2.50

+837.0%

Bull

$8.00

+2898.5%

12-Month Target Range8 analysts

$0.50$2.50$8.00

Current $0.27Consensus

Current Price

$0.27

Upside to Consensus

$2.23

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+651.17%

EPS—

FY2028

Rev-26.50%

EPS—

FY2029

Rev+61.22%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$13M	$10M	$16M	$98M
Low	$2M	$13M	$5M	$15M	$92M
High	$2M	$14M	$15M	$17M	$103M
EBITDA Avg	$-8M	$-3M	$-9M	$-11M	$306,850
Low	$-10M	$-9M	$-10M	$-12M	$198,479
High	$-5M	$4M	$-8M	$-10M	$415,222
EBIT Avg	$-8M	$-4M	$-10M	$-12M	$-548,905
Low	$-11M	$-10M	$-11M	$-13M	$-657,276
High	$-6M	$3M	$-8M	$-11M	$-440,533
Net Income Avg	$-10M	$-5M	$-11M	$-13M	$-2M
Low	$-12M	$-11M	$-12M	$-14M	$-2M
High	$-7M	$2M	$-9M	$-12M	$-1M
EPS Avg	$-0.06	$-0.03	$-0.07	$-0.08	$-0.01
Low	$-0.07	$-0.07	$-0.07	$-0.09	$-0.01
High	$-0.04	$0.01	$-0.06	$-0.07	$-0.01
Analysts (Rev / EPS)	4 / 4	4 / 4	2 / 2	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$5M	$33,333	—	—	$39,000	$114,000
Low	$5M	$33,333	—	—	$39,000	$114,000
High	$5M	$33,333	—	—	$39,000	$114,000
EBITDA Avg	$-2M	$-3M	—	—	$-3M	—
Low	$-2M	$-3M	—	—	$-3M	—
High	$-2M	$-3M	—	—	$-3M	—
EBIT Avg	$-3M	$-3M	—	—	$-3M	—
Low	$-3M	$-3M	—	—	$-3M	—
High	$-3M	$-3M	—	—	$-3M	—
Net Income Avg	$-3M	$-3M	$-3M	$-3M	$-3M	$3M
Low	$-3M	$-3M	$-3M	$-3M	$-3M	$3M
High	$-3M	$-3M	$-3M	$-3M	$-3M	$3M
EPS Avg	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02	$0.02
Low	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02	$0.02
High	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02	$0.02
Analysts (Rev / EPS)	1 / 3	3 / 3	— / 1	— / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 30, 2025Jefferies

Jefferies Downgrades Mereo BipPharma Group (MREO) to Hold

Target:$0.50

+75.2%from $0.29

Dec 29, 2025Robert W. Baird

Mereo BioPharma price target lowered to $1, 'Fresh Pick' removed at Baird

Target:$1.00

+255.7%from $0.28

Dec 29, 2025BTIG

Mereo BioPharma price target lowered to $1 from $6 at BTIG

Target:$1.00

+259.2%from $0.28

Dec 18, 2025BTIG

BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)

Target:$6.00

+212.5%from $1.92

Jul 10, 2025Needham

Mereo BioPharma price target lowered to $5 from $7 at Needham

Target:$5.00

+168.1%from $1.86

Jun 20, 2024Leerink Partners

Mereo BioPharma price target raised to $8 from $6 at Leerink

Target:$8.00

+101.0%from $3.98

Jun 12, 2024Robert W. Baird

Baird Starts Mereo BipPharma Group (MREO) at Outperform

Target:$8.00

+108.9%from $3.83

Jun 12, 2024Needham

Mereo BipPharma Group (MREO) PT Raised to $7 at Needham

Target:$7.00

+98.9%from $3.52

Mar 28, 2024Needham

Mereo BipPharma Group (MREO) PT Raised to $6 at Needham on increased 'launch expectations for setrusumab in OI'

Target:$6.00

+100.0%from $3.00

Aug 12, 2022Cantor Fitzgerald

Cantor Fitzgerald Initiates Coverage On Mereo BioPharma Group with Overweight Rating, Announces Price Target of $4

Target:$4.00

+196.3%from $1.35

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance